focus -WSS

focus

author：explore 2025-10-01 20:16:43 - browse：3943

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： To avoid data mishandling cases, universities eye AI and other tools

WSS

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Medicare threatens to cut off funding for HCA's Mission hospital

Industry veterans launch new biotech VC with $310M

As Taiwan prepares for anti

For Medicare Advantage, Democrats want stronger protections around AI

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Doctors' information doesn't help them choose wisely when sick

How one medical school became remarkably diverse

Robert F. Kennedy is pitching centrism on health, even on abortion

Apple is now the first public company to be valued at $3 trillion

Medical mystery: When a cough is not just a cough

As demand for Covid shots wanes, Moderna seeks its next success

What to know about Saharan dust affecting the US and how it can affect health

knowledge

Organ transplantation is at a crossroads. Major reform is needed

Organ transplantation is at a crossroads. Major reform is needed

Gilead might be held responsible for not developing a drug

Biogen Alzheimer’s drug launch off to slow start

The Readout: Gilead, Bernie Sanders, and other pharma news

What to know about Saharan dust affecting the US and how it can affect health

entertainment

hotspot

hotspot

explore